How Many Doses Vial Thymosin Alpha-1? Dosing Guide

A 72-week study published in the Journal of Immunology found Thymosin Alpha-1 (Tα1) delivered via subcutaneous injection at 1.6mg twice weekly produced measurable increases in CD4+ T-cell counts in immunocompromised subjects. But the study didn't address what most researchers actually struggle with: how to calculate per-vial dose yield when you're working with lyophilised powder that requires reconstitution.

Our team has guided researchers through peptide reconstitution protocols for over eight years. The gap between getting accurate dose counts and wasting expensive research material comes down to three things most guides never mention: reconstitution volume, syringe precision, and dead space losses.

How many doses does a vial of Thymosin Alpha-1 contain?

A standard 5mg Thymosin Alpha-1 vial yields 15 to 30 research doses depending on reconstitution volume and per-dose target concentration. Using 2mL bacteriostatic water produces a 2.5mg/mL solution. Each 0.2mL administration delivers approximately 0.5mg, yielding 10 usable doses per vial. Researchers targeting lower per-dose amounts (0.3–0.4mg) achieve 12–16 doses per 5mg vial.

The Reconstitution Math Most Researchers Get Wrong

The single most common error in calculating many doses vial Thymosin Alpha-1 yields isn't contamination. It's assuming the entire reconstituted volume is usable. It's not. Every syringe has dead space: the residual volume trapped in the needle hub and plunger mechanism after injection. For a standard 1mL insulin syringe with a 29-gauge needle, dead space averages 0.02–0.04mL per draw. Which means over 10 draws, you're losing 0.2–0.4mL of solution that never reaches the injection site.

Here's what that means in practice: reconstitute a 5mg vial with 2mL bacteriostatic water, and you have a 2.5mg/mL solution. Plan for ten 0.2mL doses (0.5mg each), and the math says you should get exactly 10 doses. But account for dead space. 0.03mL per draw × 10 draws = 0.3mL lost. And your actual usable volume drops to 1.7mL, yielding only 8.5 full doses. The tenth dose comes up short.

This is why experienced researchers using Thymosin Alpha-1 slightly over-reconstitute. Adding 2.2mL instead of 2.0mL compensates for dead space losses without meaningfully diluting per-dose concentration. The resulting solution (2.27mg/mL instead of 2.5mg/mL) still delivers the target dose range while ensuring full vial utilisation.

Thymosin Alpha-1 Vial Sizes and Standard Reconstitution Volumes

Thymosin Alpha-1 for research is supplied in three standard vial sizes: 2mg, 5mg, and 10mg lyophilised powder. Each requires precise reconstitution to achieve consistent per-dose accuracy. The reconstitution volume you choose determines both solution concentration and total dose count. There's no universal standard, but the ranges below reflect typical research protocols.

2mg vial: Reconstitute with 1.0–1.5mL bacteriostatic water. Using 1mL yields a 2mg/mL solution. Each 0.2mL draw delivers 0.4mg, producing 5 full doses. Using 1.5mL yields a 1.33mg/mL solution. Each 0.3mL draw delivers approximately 0.4mg, producing 5 doses with lower per-injection volume.

5mg vial: Reconstitute with 2.0–3.0mL bacteriostatic water. The most common protocol uses 2mL (2.5mg/mL concentration), yielding ten 0.5mg doses at 0.2mL per injection. Researchers targeting 0.3–0.4mg per dose use 2.5mL reconstitution volume, producing 12–15 doses.

10mg vial: Reconstitute with 4.0–5.0mL bacteriostatic water. Using 4mL produces a 2.5mg/mL solution. Twenty 0.5mg doses at 0.2mL each. Using 5mL dilutes to 2mg/mL, allowing more precise lower-dose protocols (0.3–0.4mg per draw) with 25–30 total doses.

The concentration you choose isn't arbitrary. It's driven by syringe precision limits. Insulin syringes measure reliably down to 0.01mL increments, but drawing volumes below 0.15mL increases measurement error. Reconstituting a 5mg vial with 5mL of water (1mg/mL) would require 0.5mL draws to hit a 0.5mg dose. Perfectly feasible. But targeting 0.3mg per dose at 1mg/mL concentration means drawing 0.3mL repeatedly, which insulin syringes handle well. The issue arises when researchers try to hit very low per-dose targets (0.2mg or less) with overly dilute solutions. Drawing 0.1mL consistently on a 1mL syringe introduces unacceptable variance.

What Determines Usable Dose Count Per Vial

Calculating how many doses vial Thymosin Alpha-1 provides requires more than dividing total milligrams by target dose. Three factors determine actual usable yield: syringe dead space (already covered), storage duration limits, and reconstitution technique.

Storage duration: Once reconstituted with bacteriostatic water, Thymosin Alpha-1 remains stable for 28 days when refrigerated at 2–8°C. This is a regulatory constraint, not a chemical stability limit. Bacteriostatic water contains benzyl alcohol as a preservative, which maintains antimicrobial activity for four weeks. Beyond 28 days, bacterial contamination risk increases even if the peptide itself hasn't degraded. For researchers running protocols that span more than 28 days, this dictates vial size selection. A 10mg vial reconstituted for thirty 0.33mg doses works only if all 30 doses are used within the four-week window. If your protocol calls for twice-weekly dosing (8 doses per month), a 5mg vial is the better choice.

Reconstitution technique: Injecting bacteriostatic water directly onto the lyophilised peptide cake causes foaming, which denatures protein structure and reduces bioavailability. Proper technique injects water down the vial wall. The liquid reconstitutes the powder by diffusion rather than agitation. Researchers who shake or invert the vial aggressively to speed dissolution often lose 10–15% of peptide activity to aggregation. The peptide is still present in solution, but it's no longer bioactive. This doesn't change dose count. It changes dose potency, which is harder to detect without lab assay.

We've worked with research teams across peptide reconstitution protocols for nearly a decade. The pattern we see most often: researchers overestimate usable yield by ignoring dead space and underestimate stability duration by extending beyond the 28-day bacteriostatic window. Both mistakes compound when working with 10mg vials targeting 0.3mg per dose. The math says 33 doses, but actual usable yield accounting for losses is closer to 28.

Thymosin Alpha-1: Dose Count Comparison by Vial Size

| Vial Size | Reconstitution Volume | Solution Concentration | Target Dose per Injection | Doses per Vial (Theoretical) | Usable Doses (Accounting for Dead Space) | Professional Assessment | |---|---|---|---|---|---| | 2mg | 1.0mL | 2mg/mL | 0.4mg | 5 | 4–5 | Best for short pilot studies; limited dose flexibility | | 5mg | 2.0mL | 2.5mg/mL | 0.5mg | 10 | 8–9 | Most common research vial; balances cost and 28-day stability window | | 5mg | 2.5mL | 2mg/mL | 0.4mg | 12.5 | 11–12 | Preferred for lower per-dose protocols without switching vial size | | 10mg | 4.0mL | 2.5mg/mL | 0.5mg | 20 | 18–19 | Requires high-frequency dosing protocols to use within 28 days | | 10mg | 5.0mL | 2mg/mL | 0.33mg | 30 | 27–28 | Maximum yield; only viable for daily or near-daily administration schedules |

What If: Thymosin Alpha-1 Dosing Scenarios

What If I Need Doses Smaller Than 0.3mg Per Injection?

Dilute further during reconstitution to increase per-dose draw volume and improve measurement precision. Reconstituting a 5mg vial with 5mL bacteriostatic water produces a 1mg/mL solution. Drawing 0.2mL delivers exactly 0.2mg, which insulin syringes measure reliably. The trade-off: higher reconstitution volumes mean fewer total doses per vial due to dead space scaling with draw count. A 5mg vial at 1mg/mL concentration yields 20–22 usable 0.2mg doses instead of 25 theoretical doses.

What If My Protocol Requires 15 Doses But I Only Have 5mg Vials?

Reconstitute with 2.5mL bacteriostatic water to produce a 2mg/mL solution, then target 0.33mg per dose by drawing 0.165mL per injection. This yields approximately 15 doses per 5mg vial when accounting for dead space. Measuring 0.165mL on a 1mL insulin syringe requires careful technique. Mark the syringe at the midpoint between 0.15mL and 0.17mL graduations. Alternatively, round to 0.17mL per draw (0.34mg per dose), which simplifies measurement and still delivers 14 usable doses.

What If I Miss the 28-Day Stability Window?

Discard the vial and reconstitute a fresh one. Bacteriostatic water loses antimicrobial efficacy beyond four weeks, even under refrigeration. Continuing to draw from an expired vial introduces contamination risk that no visual inspection can detect. Thymosin Alpha-1 peptide degradation after 28 days is minimal (estimated 5–8% potency loss), but bacterial contamination in a multi-dose vial without active preservative is a genuine hazard. Researchers working with infrequent dosing schedules (once weekly or less) should use smaller vial sizes to avoid waste.

The Unvarnished Truth About Thymosin Alpha-1 Dose Calculations

Here's the honest answer: most dose-per-vial calculators you'll find online assume perfect technique, zero waste, and theoretical draw volumes that don't account for how syringes actually work. The numbers look clean. 5mg vial ÷ 0.5mg per dose = 10 doses. But real-world yield is consistently 15–20% lower because of dead space, overfill losses during the first draw, and measurement variance when targeting very precise small volumes.

The bigger issue is that researchers optimising for maximum dose count per vial often choose reconstitution volumes that make accurate dosing harder. Diluting a 10mg vial with 10mL of water to squeeze out 30+ doses at 0.33mg each sounds economical until you're trying to draw 0.165mL repeatedly with an insulin syringe. At that point, dose-to-dose variance exceeds 10%, which negates any cost savings.

Our team's recommendation after working with hundreds of peptide research protocols: optimise for measurement precision first, dose count second. Reconstitute to concentrations that allow draw volumes between 0.15mL and 0.4mL. That's the sweet spot for insulin syringe accuracy. Accept that a 5mg vial yields 8–9 usable doses instead of 10 theoretical ones. The consistency gain outweighs the marginal material cost.

Researchers serious about Thymosin Alpha-1 work understand that small-batch synthesis with exact amino-acid sequencing. The standard Real Peptides maintains across compounds like Thymalin and Dihexa. Matters more than vial size arbitrage. Precision at the molecular level during synthesis translates directly to dose consistency during reconstitution.

If vial waste concerns you, the answer isn't stretching a 10mg vial across six weeks. It's matching vial size to protocol cadence so you're replacing vials before the 28-day stability limit rather than after. That's not a peptide problem. That's a planning problem.

faqs

[ { "question": "How many doses are in a 5mg vial of Thymosin Alpha-1?", "answer": "A 5mg Thymosin Alpha-1 vial reconstituted with 2mL bacteriostatic water yields 8 to 10 usable research doses at 0.5mg per administration. Theoretical yield is 10 doses, but syringe dead space (0.02–0.04mL per draw) reduces actual usable volume by 0.2–0.4mL over the course of multiple injections. Researchers targeting smaller per-dose amounts (0.3–0.4mg) can achieve 11–12 doses per vial by using 2.5mL reconstitution volume instead." }, { "question": "What is the correct reconstitution volume for Thymosin Alpha-1?", "answer": "The most common reconstitution protocol uses 2mL bacteriostatic water per 5mg vial, producing a 2.5mg/mL solution that allows accurate measurement of 0.5mg doses at 0.2mL per draw. Researchers can use 1.5–3.0mL depending on target dose size. Lower volumes (1.5mL) create more concentrated solutions for smaller injection volumes, while higher volumes (3.0mL) reduce concentration to allow more precise targeting of very small per-dose amounts. The key constraint is syringe measurement precision: draw volumes below 0.15mL increase dosing variance." }, { "question": "How long does reconstituted Thymosin Alpha-1 remain stable?", "answer": "Reconstituted Thymosin Alpha-1 stored at 2–8°C remains stable for 28 days when mixed with bacteriostatic water. This limit is set by the antimicrobial preservative (benzyl alcohol) in bacteriostatic water, not by peptide degradation. The Tα1 molecule itself degrades minimally over four weeks under refrigeration. Beyond 28 days, bacterial contamination risk increases even though the peptide retains most of its potency. Researchers should discard vials after the 28-day window and reconstitute fresh material rather than extending use." }, { "question": "Can I use a 10mg vial for lower per-dose protocols to save cost?", "answer": "Yes, but only if your administration schedule allows full vial use within 28 days. A 10mg vial reconstituted with 5mL bacteriostatic water yields approximately 28 usable doses at 0.33mg per injection. But that requires near-daily dosing to consume the vial before the stability window closes. For protocols with twice-weekly or weekly dosing, a 5mg vial is more appropriate despite higher per-dose cost. Using oversized vials for infrequent protocols results in material waste when the unused portion must be discarded at day 28." }, { "question": "What causes Thymosin Alpha-1 dose count to be lower than expected?", "answer": "Syringe dead space is the primary cause. Standard insulin syringes retain 0.02–0.04mL of solution in the needle hub and plunger mechanism after each injection. Over 10 draws, this cumulative loss totals 0.2–0.4mL, reducing a 2mL reconstituted vial to 1.6–1.8mL of usable volume. Secondary causes include overfill waste during the first draw (air displacement when piercing the vial stopper) andfoaming during reconstitution if water is injected directly onto the peptide powder rather than down the vial wall." }, { "question": "How do I calculate per-dose concentration for Thymosin Alpha-1?", "answer": "Divide total peptide mass by reconstitution volume: a 5mg vial reconstituted with 2mL bacteriostatic water produces 5mg ÷ 2mL = 2.5mg/mL concentration. To determine dose per injection, multiply solution concentration by draw volume: 2.5mg/mL × 0.2mL = 0.5mg per injection. Researchers can reverse-engineer this formula to find the reconstitution volume needed for a target dose: if you want 0.4mg per 0.2mL draw, you need 0.4mg ÷ 0.2mL = 2mg/mL concentration, which requires reconstituting 5mg with 2.5mL water." }, { "question": "Does Thymosin Alpha-1 vial size affect peptide purity or potency?", "answer": "No. Vial size reflects peptide quantity, not quality. A 2mg vial, 5mg vial, and 10mg vial of Thymosin Alpha-1 synthesised under identical USP standards contain the same amino-acid sequence and purity level (typically ≥98% by HPLC). The only practical difference is dose economy: larger vials offer lower per-milligram cost but require higher-frequency protocols to use the reconstituted material within the 28-day bacteriostatic stability window. Researchers should select vial size based on protocol cadence and target dose count, not an assumption that larger vials are higher quality." }, { "question": "What syringe type is best for drawing Thymosin Alpha-1 doses?", "answer": "Standard 1mL insulin syringes with 29-gauge or 30-gauge needles provide the best balance of measurement precision and low dead space for Thymosin Alpha-1 administration. These syringes measure accurately down to 0.01mL increments and have dead space volumes of 0.02–0.04mL per draw. Avoid tuberculin syringes (which have higher dead space) and avoid syringes smaller than 0.5mL (which limit maximum usable draw volume). For protocols requiring very small doses (0.2mg or less), consider 0.5mL insulin syringes with 31-gauge needles to further reduce dead space losses." }, { "question": "Can Thymosin Alpha-1 be reconstituted with sterile water instead of bacteriostatic water?", "answer": "Yes, but only for single-use vials intended for immediate administration. Sterile water lacks the benzyl alcohol preservative found in bacteriostatic water, so reconstituted peptide must be used within 24 hours to avoid bacterial contamination. Multi-dose vials. Any vial from which more than one dose will be drawn over multiple days. Require bacteriostatic water to maintain antimicrobial activity across the 28-day usage period. Researchers reconstituting with sterile water should draw the entire vial contents into individual syringes immediately after mixing, then freeze unused doses at −20°C for later use." }, { "question": "What is the difference between Thymosin Alpha-1 and Thymosin Beta-4?", "answer": "Thymosin Alpha-1 (Tα1) and Thymosin Beta-4 (Tβ4) are distinct peptides with different mechanisms and research applications. Tα1 is a 28-amino-acid immunomodulatory peptide that enhances T-cell maturation and cytokine production. Research focuses on immune function and antiviral activity. Tβ4 is a 43-amino-acid regenerative peptide that promotes angiogenesis, cell migration, and tissue repair. Research targets wound healing and cardiovascular recovery. The two peptides are not interchangeable, and dose calculations for one do not apply to the other." } ] }

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on Thymosin Alpha-1 indexed in PubMed, listed for research context. Real Peptides supplies Thymosin Alpha-1 for laboratory research use only.

1. Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells. Cancer research, 2026. PMID 42295795. doi:10.1158/0008-5472.CAN-25-5547
2. The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets. OncoTargets and therapy, 2025. PMID 40955371. doi:10.2147/OTT.S527785
3. Aging and Thymosin Alpha-1. International journal of molecular sciences, 2025. PMID 41373628. doi:10.3390/ijms262311470
4. Interferon-α and thymosin-α1 plus tislelizumab enhance CD8(+) T cell cytotoxicity toward pancreatic ductal adenocarcinoma. iScience, 2025. PMID 40727936. doi:10.1016/j.isci.2025.113053
5. Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy. Cell reports. Medicine, 2024. PMID 39357524. doi:10.1016/j.xcrm.2024.101751
6. Enhanced Immunomodulatory Effects of Thymosin-Alpha-1 in Combination with Polyanionic Carbosilane Dendrimers against HCMV Infection. International journal of molecular sciences, 2024. PMID 38396631. doi:10.3390/ijms25041952
7. Thymosin α-1 in cancer therapy: Immunoregulation and potential applications. International immunopharmacology, 2023. PMID 36812669. doi:10.1016/j.intimp.2023.109744
8. Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era. International immunopharmacology, 2023. PMID 36871535. doi:10.1016/j.intimp.2023.109952